Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 10/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9029716 | 0.91 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6002048 | 0.90 | PTGS2 (0.50) | PTGS2NR4A2PTGS1RXRA | |
| SCHEMBL6002489 | 0.90 | PTGS2 (0.50) | PTGS2NR4A2PTGS1RXRA | |
| SCHEMBL9455544 | 0.89 | NR4A2 (0.60) | PTGS2NR4A2PTGS1RXRANR4A1 | |
| SCHEMBL6000535 | 0.85 | PTGS2 (0.63) | PTGS2NR4A2PTGS1RXRA | |
| SCHEMBL5089153 | 0.83 | PTGS2 (0.55) | PTGS2NR4A2PTGS1 | |
| SCHEMBL9024861 | 0.82 | PTGS2 (0.66) | PTGS2NR4A2PTGS1RXRA | |
| SCHEMBL7498544 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL7498729 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1 | |
| SCHEMBL6002492 | 0.80 | NR4A2 (0.80) | PTGS2NR4A2PTGS1RXRANR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | claimed |
| US-20060229347-A1 | Treatment of eczemas | ASTION DEVELOPMENT A/S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229347-A1 | Treatment of eczemas | ZAP70, SYK, LCK | PTGS2 792/4885NR4A2 1164/4885PTGS1 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.